Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Acute myeloid leukemia

The NF1 hotspot in acute myeloid leukemia: what’s in a name?

Leukemia volume 32, page 2715 (2018)Cite this article

Subjects

Eisfeld and colleagues [1] recently described recurrent mutations in NF1 in patients with acute myeloid leukemia (AML), with a higher frequency than seen in previous studies. They show that mutations in hotspot Thr676 are associated with lower complete remission rates and shorter overall survival in patients <60 years. One of the factors that may have contributed to the previous oversight of this hotspot in previous studies, is its location in a mononucleotide cytosine repeat, which can easily be missed due to a faulty interpretation of sequencing data.

Changes in mononucleotide repeats are cumbersome in their technical analysis but also in their nomenclature. Initiatives by the Human Genome Variation Society (HGVS) are trying to limit the nomenclature variability by providing clear guidelines [2] how to describe such variants. The authors refer to the NF1 hotspot as “p.Thr676fs*24 [c.2026dupC], Thr676”. This annotation is in conflict with the HGVS guidelines in several ways: as the DNA sequence is determined, this should be prominent, and the derived amino acid sequence should be between brackets (as it is extrapolated from the change at the DNA level). Applying this rule, the annotation would change to “c.2026dupC; p.(Thr676fs*24)”. However, no reference sequence is provided, and nucleotide 2026 is not a C in the two reference sequences (NM_000267.3 and NM_001042492.2) used to determine the Locus Reference Genomic transcripts [3]. In both transcripts, the C-stretch runs from nucleotides 2027 to 2033. As stated in the HGVS guidelines [2], for duplications in stretches of repeated sequences, the most 3′ residue is arbitrarily assigned to have been changed, resulting in a reassignment of the NF1 hotspot to c.2033 in the DNA sequence and from Thr676 to Ile679 in the protein. In conclusion, the HGVS compliant nomenclature of an additional cytosine in this C-stretch is NM_001042492.2:c.2033dup; p.(Ile679Aspfs*21). The Ile679 amino acid annotation is also used in the AACR GENIE dataset, to which the authors refer to confirm their results. The recognition of Ile679 as a hotspot for NF1 mutations, if confirmed in other studies, would benefit significantly from the use of a uniform nomenclature, following the HGVS guidelines.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Eisfeld AK, Kohlschmidt J, Mrozek K, Mims A, Walker CJ, Blachly JS, et al. NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia. 2018. https://doi.org/10.1038/s41375-018-0147-4

    Article  CAS  Google Scholar 

  2. den Dunnen JT. Sequence variant descriptions: HGVS nomenclature and mutalyzer. Curr Protoc Hum Genet. 2016;90:7.13.1–7.13.19.

    Google Scholar 

  3. MacArthur JA, Morales J, Tully RE, Astashyn A, Gil L, Bruford EA, et al. Locus reference genomic: reference sequences for the reporting of clinically relevant sequence variants. Nucleic Acids Res. 2014;42:D873–8. (Database issue)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory for Molecular Hematology, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium

    Karl Vandepoele, Joni Van der Meulen & Barbara Denys

  2. Molecular Diagnostics Ghent, Ghent University Hospital, Corneel Heymanslaan 10, 9000, Ghent, Belgium

    Karl Vandepoele, Joni Van der Meulen & Barbara Denys

Authors
  1. Karl Vandepoele
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joni Van der Meulen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barbara Denys
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Vandepoele.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vandepoele, K., Van der Meulen, J. & Denys, B. The NF1 hotspot in acute myeloid leukemia: what’s in a name?. Leukemia 32, 2715 (2018). https://doi.org/10.1038/s41375-018-0266-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-018-0266-y

This article is cited by

Search

Advanced search

Quick links